Ovid Therapeutics
OVID
72 hedge funds and large institutions have $113M invested in Ovid Therapeutics in 2021 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 20 increasing their positions, 26 reducing their positions, and 19 closing their positions.
0.21% more ownership
Funds ownership: 49.24% → 49.45% (+0.21%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
10% less funds holding
Funds holding: 80 → 72 (-8)
14% less capital invested
Capital invested by funds: $131M → $113M (-$17.7M)
23% less repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 26
42% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 19
44% less call options, than puts
Call options by funds: $1.17M | Put options by funds: $2.09M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$4.57M |
| 2 |
GC
Globeflex Capital
San Diego,
California
|
+$1.42M |
| 3 |
PIM
Platinum Investment Management
Sydney Australia 2000,
Australia
|
+$1.35M |
| 4 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$1.22M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$366K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
-$1.46M |
| 2 |
Millennium Management
New York
|
-$1.29M |
| 3 |
AQR Capital Management
Greenwich,
Connecticut
|
-$1.18M |
| 4 |
Two Sigma Investments
New York
|
-$1.13M |
| 5 |
Two Sigma Advisers
New York
|
-$818K |
OVID Hedge Fund Activity: Q3 2021 in Review
72 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in Ovid Therapeutics (OVID) for Q3 2021, worth a combined $113M — down 14% from $131M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of OVID and 11 opened new positions — a net loss of 8 holders — while 26 trimmed existing stakes and 20 added.
The largest buyer was Stonepine Capital Management, adding an estimated $4.57M. The largest seller was Tekla Capital Management, exiting entirely with an estimated $1.46M sold.
- 72 institutional investors held Ovid Therapeutics (OVID) as of Q3 2021, down from 80 in Q2 2021.
- Funds reported $113M of Ovid Therapeutics stock for Q3 2021, down 14% quarter-over-quarter.
- 11 funds opened new Ovid Therapeutics positions in Q3 2021 and 19 closed out, a net change of -8 holders.
- The largest Ovid Therapeutics buyer in Q3 2021 was Stonepine Capital Management, an estimated $4.57M added.
- The largest Ovid Therapeutics seller in Q3 2021 was Tekla Capital Management, an estimated $1.46M sold.
Based on aggregated 13F filings for Q3 2021.